{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Votrient", "query": { "intervention": "Votrient" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 156, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Votrient&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T04:25:05.758Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00674024", "title": "Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Lymphoma" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib (GW786034)(GW786034)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "18 Years to 110 Years" }, "enrollment_count": 8, "start_date": "2008-10-07", "completion_date": "2013-01-22", "has_results": false, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-09-08T04:25:05.758Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00674024" }, { "nct_id": "NCT01262820", "title": "Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2010-12", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-09-08T04:25:05.758Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01262820" }, { "nct_id": "NCT04199026", "title": "Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Sarcoma", "Recurrent Sarcoma", "Resectable Sarcoma" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Drug Delivery Microdevice", "type": "DEVICE" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Ganitumab", "type": "BIOLOGICAL" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Polyethylene Glycol", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 20, "start_date": "2025-02-25", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-08T04:25:05.758Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04199026" }, { "nct_id": "NCT00347919", "title": "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "pazopanib (GW786034) 400 mg", "type": "DRUG" }, { "name": "lapatinib (GW572016) 1500 mg", "type": "DRUG" }, { "name": "lapatinib (GW572016) 1000 mg", "type": "DRUG" }, { "name": "pazopanib (GW786034) 800 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 189, "start_date": "2006-07", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-02-25", "last_synced_at": "2026-09-08T04:25:05.758Z", "location_count": 19, "location_summary": "Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00347919" }, { "nct_id": "NCT00720941", "title": "Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1110, "start_date": "2008-08-14", "completion_date": "2021-03-24", "has_results": true, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-09-08T04:25:05.758Z", "location_count": 96, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 82 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720941" }, { "nct_id": "NCT03139331", "title": "PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Refractory Sarcoma" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "6 Years to 30 Years" }, "enrollment_count": 16, "start_date": "2017-06-06", "completion_date": "2020-09-30", "has_results": false, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-08T04:25:05.758Z", "location_count": 3, "location_summary": "Oakland, California • San Francisco, California • Boston, Massachusetts", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03139331" }, { "nct_id": "NCT00158782", "title": "Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "GW786034", "type": "DRUG" }, { "name": "lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 75, "start_date": "2004-09-28", "completion_date": "2007-08-21", "has_results": false, "last_update_posted_date": "2017-11-17", "last_synced_at": "2026-09-08T04:25:05.758Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00158782" }, { "nct_id": "NCT00450879", "title": "Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Carcinoma", "Recurrent Breast Carcinoma", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer" ], "interventions": [ { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2007-01", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-09-08T04:25:05.758Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450879" }, { "nct_id": "NCT00749320", "title": "Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Arterial Spin Labeling Magnetic Resonance Imaging", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2008-09", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2020-02-26", "last_synced_at": "2026-09-08T04:25:05.758Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00749320" }, { "nct_id": "NCT02204371", "title": "Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Telangiectasia, Hereditary Hemorrhagic" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 7, "start_date": "2015-02-25", "completion_date": "2016-02-10", "has_results": true, "last_update_posted_date": "2017-07-06", "last_synced_at": "2026-09-08T04:25:05.758Z", "location_count": 5, "location_summary": "Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02204371" } ] }